主要文件

查看所有文档

67298

强的松

Name: 强的松
Brand: SIAL

pharmaceutical secondary standard; traceable to USP, PhEur and BP

别名:

1-可的松, 17Α,21-二羟基-1,4-孕甾二烯-3,11,20-三酮, 去氢可的松, 强的松

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₂₁H₂₆O₅

化学文摘社编号:

53-03-2

分子量:

358.43

EC Number:

200-160-3

UNSPSC Code:

41116107

PubChem Substance ID:

329760538

Beilstein/REAXYS Number:

2065301

MDL number:

MFCD00003608

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

certified reference material, pharmaceutical secondary standard

agency

traceable to BP 553, traceable to Ph. Eur. P2900000, traceable to USP 1559006

technique(s)

HPLC: suitable, gas chromatography (GC): suitable

mp

236-238 °C (lit.)

format

neat

SMILES string

O=C1C=C[C@@]2(C)C(CC[C@]([C@@](CC[C@@]3(C(CO)=O)O)([H])[C@]3(C)C4)([H])[C@]2([H])C4=O)=C1

InChI

1S/C21H26O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-15,18,22,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1

InChI key

XOFYZVNMUHMLCC-ZPOLXVRWSA-N

Gene Information

human ... NR3C1(2908)

说明

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Still not finding the right product?

Explore all of our products under 强的松

pictograms

GHS08

signalword

Warning

hcodes

H373

Hazard Classifications

STOT RE 2

存储类别

11 - Combustible Solids

pcodes

P260 - P314 - P501

法规信息

新产品

此项目有

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.

Ronald de Wit

European journal of cancer (Oxford, England : 1990), 41(4), 502-507 (2005-03-02)

Until now, the use of systemic chemotherapy for advanced androgen-independent prostate cancer has had very little to offer to patients. However, in 2004, two large randomised trials investigating docetaxel vs. mitoxantrone have both demonstrated survival improvements, and, in one of

Dexamethasone versus prednisone for induction therapy in childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.

O Teuffel et al.

Leukemia, 25(8), 1232-1238 (2011-04-30)

This systematic review and meta-analysis compared the efficacy and toxicity of dexamethasone (DEX) versus prednisone (PRED) for induction therapy in childhood acute lymphoblastic leukemia (ALL). We searched biomedical literature databases and conference proceedings for randomized controlled trials comparing DEX and

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.

Ian F Tannock et al.

The Lancet. Oncology, 14(8), 760-768 (2013-06-08)

Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the

查看所有相关文献

全球贸易项目编号

货号	GTIN
CDS024860-10MG	04061829277291